Abstract 158P
Background
The contribution of cross-presenting XCR1+ dendritic cells (DCs) and SIRPα+ DCs in maintaining T cell function in chronic infection has been previously described by our group, but their impact in cancer immunotherapy remains unexplored. We report results from the prespecified translational analysis in VENEZOLUNG trial and preliminary efficacy and safety data.
Methods
VENEZOLUNG is an open-label, phase 1b/2 trial evaluating the safety and efficacy of autologous tumor lysate-pulsed DC product combined with atezolizumab as maintenance therapy in extensive stage small cell lung cancer (ES-SCLC). After standard induction, patients received up to six doses of mature DCs intradermally and atezolizumab 1200 mg iv every three weeks. The dynamic interplay between the DC populations and exhausted CD8+ T cell subsets was analyzed in patient blood samples by flow cytometry to assess markers of T cell exhaustion, effector regulatory T cells, gamma delta T cells, and XCR1+cDC1, exploring correlations with clinical outcomes.
Results
20 patients enrolled, mostly PD-L1 negative (75%) and SCLC-A subtype (58%). Seventeen patients completed DC vaccination (median doses 3, range 1-6). Treatment-related adverse events (TRAEs) occurred in 80% of patients, most grade 1-2. Grade 3-4 TRAEs were chemotherapy related: neutropenia (25%), anemia (15%), thrombocytopenia (10%) and lymphopenia (5%). DC vaccination side effects were grade 1-2 injection site irritation (15%). Overall response was 94%. After a median follow up of 17.4 months (m), median progression free survival was 4.7 m (95% CI, 4.2 to 5.8) and overall survival (OS) 11.6 m (95%CI 6.3, 17.9). PBMCs pre- and post-treatment from 10 patients showed those with expansion of circulating XCR1+ DC (n=6) had a parallel increase in CXCR5+PD-1+ follicular helper CD8 T cells and a median OS of 26 m (95% CI, 6.8, NA) vs 6.3 m (95% CI, 5-12.1) in patients without significant XCR1+ DC expansion (p=0.035). Decrease of Tpex (CXCR5+ PD1+ non-naive CD8+ T cells), cDC1s, cDC2scorrelated with higher risk of death (p-value <0.05).
Conclusions
The role of XCR1+ DCs could be crucial for checkpoint inhibitor-based therapy.
Clinical trial identification
NCT04487756.
Legal entity responsible for the study
Institut Oncologico Dr Rosell (IOR).
Funding
Roche.
Disclosure
M. Gonzalez Cao: Non-Financial Interests, Institutional, Sponsor/Funding: Roche, Regeneron, Astra zeneca, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract